109 filings
Page 5 of 6
8-K
a7w5rgk4 0ayfswg
8 Aug 17
Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
12:00am
8-K
piah0my oer3xwy
26 Jun 17
Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
12:00am
8-K/A
d3yhqcqk pow1vp
26 Jun 17
Regulation FD Disclosure
12:00am
8-K
0uqhjrfbwhl2dvs57yk
5 Jun 17
Regulation FD Disclosure
12:00am
8-K
8avtp
28 Apr 17
Entry into a Material Definitive Agreement
12:00am
8-K
k36v5b cw677
18 Apr 17
Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
12:00am
8-K
z3ivg3
3 Apr 17
Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update
12:00am
8-K
8a5c f5lfh7hmo85
30 Mar 17
Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors
12:00am
8-K
jbrt5
19 Jan 17
Matinas BioPharma Successfully Completes Warrant Tender Offer– Raises $13.5 Million from Exercise of Warrants
12:00am
8-K
rs3mu8mn3rk4o ew1zj
21 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
dq584ue78
13 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
6nq3r6
6 Oct 16
Regulation FD Disclosure
12:00am
8-K
xxzmguj
13 Sep 16
Matinas BioPharma Completes Private Placement of $8.0 Million
12:00am
8-K
ffjzu7
1 Aug 16
Entry into a Material Definitive Agreement
12:00am
8-K
fgzo6yy 1dvk
9 Mar 16
Departure of Directors or Certain Officers
12:00am
8-K
6a1c6d6fktd35f9qy6nb
5 Nov 15
Submission of Matters to a Vote of Security Holders
12:00am
8-K
2dc2mluxoln2doz 9hco
1 Oct 15
Departure of Directors or Certain Officers
12:00am
8-K
lr4q6mw
9 Sep 15
Regulation FD Disclosure
12:00am
8-K
dzxage0qa
1 Sep 15
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
12:00am
8-K
e3012d3ft u00fh
18 Aug 15
Other Events
12:00am